Switzerland-based Novimmune, which counts Fracht as an investor, has now raised almost $230m and is working on cancer, inflammatory and autoimmune disease treatments.

Fabien Mondini, Sabic Ventures' senior investment manager in Europe since 2012, has left its parent company, chemicals and advanced materials producer Sabic.

Commerzbank's corporate venturing unit co-led the series B round, which will be used to expand Mambu's team and fund international growth.

Johnson & Johnson will subscribe for new shares in Alligator Bioscience as part of a licensing agreement for its immuno-oncology drug candidate.

Aelix Therapeutics will use the $12.7m of funding to advance its HIV vaccine candidate through phase 2 clinical trials.

The Belgium-based stem cell therapy developer, which is backed by investors including Gri-Cel and Novartis, has filed to go public in the US.

Yahoo Japan was among the new investors in a round that values the flight and travel booking service a $1.6bn.